FR2606279A1 - New compositions containing Oenothera oil and products that block the formation of singlet oxygen and free radicals - Google Patents
New compositions containing Oenothera oil and products that block the formation of singlet oxygen and free radicals Download PDFInfo
- Publication number
- FR2606279A1 FR2606279A1 FR8616154A FR8616154A FR2606279A1 FR 2606279 A1 FR2606279 A1 FR 2606279A1 FR 8616154 A FR8616154 A FR 8616154A FR 8616154 A FR8616154 A FR 8616154A FR 2606279 A1 FR2606279 A1 FR 2606279A1
- Authority
- FR
- France
- Prior art keywords
- skin
- formation
- products
- compositions
- free radicals
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 35
- 230000015572 biosynthetic process Effects 0.000 title claims abstract description 6
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 title abstract description 3
- 241000219925 Oenothera Species 0.000 title abstract 2
- 239000002537 cosmetic Substances 0.000 claims abstract description 12
- 239000000284 extract Substances 0.000 claims description 21
- 210000000952 spleen Anatomy 0.000 claims description 14
- 235000008524 evening primrose extract Nutrition 0.000 claims description 12
- 229940089020 evening primrose oil Drugs 0.000 claims description 12
- 239000010475 evening primrose oil Substances 0.000 claims description 12
- 210000001519 tissue Anatomy 0.000 claims description 8
- 239000006071 cream Substances 0.000 claims description 7
- 239000003921 oil Substances 0.000 claims description 6
- 235000013336 milk Nutrition 0.000 claims description 5
- 239000008267 milk Substances 0.000 claims description 5
- 210000004080 milk Anatomy 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 239000000499 gel Substances 0.000 claims description 4
- 230000000903 blocking effect Effects 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 150000003505 terpenes Chemical class 0.000 claims description 3
- 235000007586 terpenes Nutrition 0.000 claims description 3
- 244000000626 Daucus carota Species 0.000 claims description 2
- 235000002767 Daucus carota Nutrition 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 2
- 229940087168 alpha tocopherol Drugs 0.000 claims 1
- 229960000984 tocofersolan Drugs 0.000 claims 1
- 239000002076 α-tocopherol Substances 0.000 claims 1
- 235000004835 α-tocopherol Nutrition 0.000 claims 1
- 210000003491 skin Anatomy 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 7
- -1 biological extracts Chemical class 0.000 description 7
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 6
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 229940095074 cyclic amp Drugs 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 230000005855 radiation Effects 0.000 description 5
- HOVAGTYPODGVJG-UVSYOFPXSA-N (3s,5r)-2-(hydroxymethyl)-6-methoxyoxane-3,4,5-triol Chemical compound COC1OC(CO)[C@@H](O)C(O)[C@H]1O HOVAGTYPODGVJG-UVSYOFPXSA-N 0.000 description 4
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 235000004626 essential fatty acids Nutrition 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- HOVAGTYPODGVJG-UHFFFAOYSA-N methyl beta-galactoside Natural products COC1OC(CO)C(O)C(O)C1O HOVAGTYPODGVJG-UHFFFAOYSA-N 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 4
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 229960005305 adenosine Drugs 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 229960003160 hyaluronic acid Drugs 0.000 description 3
- 230000036571 hydration Effects 0.000 description 3
- 238000006703 hydration reaction Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 229960004418 trolamine Drugs 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 241000195955 Equisetum hyemale Species 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 230000037336 dry skin Effects 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229940100460 peg-100 stearate Drugs 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 150000008223 ribosides Chemical class 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 229960000278 theophylline Drugs 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- RTAPDZBZLSXHQQ-UHFFFAOYSA-N 8-methyl-3,7-dihydropurine-2,6-dione Chemical class N1C(=O)NC(=O)C2=C1N=C(C)N2 RTAPDZBZLSXHQQ-UHFFFAOYSA-N 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 208000005156 Dehydration Diseases 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229940008396 carrot extract Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 125000001891 dimethoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000004116 glycogenolysis Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000003711 photoprotective effect Effects 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 229940079889 pyrrolidonecarboxylic acid Drugs 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 229940045920 sodium pyrrolidone carboxylate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- ATCJTYORYKLVIA-SRXJVYAUSA-N vamp regimen Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C(C45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 ATCJTYORYKLVIA-SRXJVYAUSA-N 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 150000008495 β-glucosides Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Cosmetics (AREA)
Abstract
Description
La présente invention concerne de nouvelles compositions pour les soins de la peau renfermant de l'huile d'onagre et des extraits tissulaires de rate. The present invention relates to novel skin care compositions comprising evening primrose oil and spleen tissue extracts.
L'invention a pour objet de nouvelles compositions cosmétiques ou dermatologiques pour les soins de la peau, caractérisées en ce qu'elles renferment de l'huile d'onagre associée à des extraits tissulaires de rate. The subject of the invention is new cosmetic or dermatological compositions for skin care, characterized in that they contain evening primrose oil combined with tissue extracts from the spleen.
Ces nouvelles compositions sont destinées notamment a retarder les signes du vieillissement de la peau. These new compositions are intended in particular to delay the signs of aging of the skin.
Au fur et a mesure du développement du vieillissement cutané,des modifications interviennent, surtout au niveau épidermique et dermique. As the skin aging develops, changes occur, especially at the epidermal and dermal level.
Au sein de l'épiderme, la production de cellules nouvelles ne compense plus la desquamation et l'épiderme s' amincit progressivement. Within the epidermis, the production of new cells no longer compensates for flaking and the epidermis gradually thins.
Les glandes sebacées sont fonctionnellement moins actives et la peau devient alors sèche. The sebaceous glands are less functionally active and the skin becomes dry.
Au niveau du derme, la formation de collagène jeune, responsable de la tonicité cutanée, se ralentit par diminution de l'activité secrétrice des fibroblastes. Des liaisons croisées intermoléculaires au sein des fibres de collagène se multiplient, entrainant une rigidité structurale, une réduction de la capacité d'absorption d'eau, une diminution des apports nutritionnels et d'oxygène. In the dermis, the formation of young collagen, responsible for skin tone, slows down by reducing the secretory activity of fibroblasts. Intermolecular cross-links within collagen fibers multiply, resulting in structural rigidity, a reduction in water absorption capacity, a decrease in nutritional and oxygen intake.
Ces transformations néfastes provoquent une perte d'élasticité, une déshydratation, une asphyxie et une sècheresse cutanée. These harmful transformations cause a loss of elasticity, dehydration, asphyxia and dry skin.
Ces phénomènes conduisent à l'apparition de rides, notamment au niveau du visage ou la peau est particulièrement agressée par des facteurs d'origine externe (intempéries, pollution, radiations lumineuses) et par des facteurs d'origine interne (maladies, augmentation de l'age). These phenomena lead to the appearance of wrinkles, especially in the face where the skin is particularly attacked by factors of external origin (bad weather, pollution, light radiation) and by factors of internal origin (diseases, increased 'age).
De nombreuses préparations cosmétiques destinées à combattre le vieillissement de la peau existent déja sur le marché. Many cosmetic preparations intended to fight aging of the skin already exist on the market.
Ces préparations renferment des composés très variés,tels que des extraits biologiques, par exemple des extraits placentaires, du collagène, des mélanges polyvitaminés, des acides gras essentiels. These preparations contain a wide variety of compounds, such as biological extracts, for example placental extracts, collagen, polyvitamin mixtures, essential fatty acids.
Cependant, jamais encore n'avaient été associés l'huile d'onagre, très efficace pour lutter contre le dessèchement cutané pour des raisons ci-dessus mentionnées, avec des extraits tissulaires particuliers, à savoir des extraits de rate, très actifs contre le ralentissement de l'activité cellulaire cutanée. However, never before had evening primrose oil been associated, very effective in combating skin dryness for the reasons mentioned above, with particular tissue extracts, namely spleen extracts, very active against slowing skin cell activity.
L'un des constituants essentiels des compositions cosmétiques ou dermatologiques, selon l'invention, est l'huile d'onagre, substance particulierement riche en acides gras essentiels polyinsaturés, éléments nutritifs indispensables à l'organisme mais qu'il ne peut synthétiser lui-même. One of the essential constituents of cosmetic or dermatological compositions, according to the invention, is evening primrose oil, a substance particularly rich in essential polyunsaturated fatty acids, essential nutrients for the body but which it cannot synthesize itself. even.
Or, la carence en acides gras essentiels polyinsaturés, qui augmente avec l'age, conduit à trois symptomes cutanés - peau seche, - perte d'élasticité, - perte d'eau transépidermique. However, the deficiency in polyunsaturated essential fatty acids, which increases with age, leads to three skin symptoms - dry skin, - loss of elasticity, - loss of transepidermal water.
L'huile d'onagre, grâce a sa richesse en acides gras essentiels, dont l'acide -linolénique, favorise la régénération des cellules épidermiques. Evening primrose oil, thanks to its richness in essential fatty acids, including -linolenic acid, promotes the regeneration of epidermal cells.
En effet, les acides gras polyinsaturés (acide linoléique, acide linolénique, acide arachidonique)sont indispensables à l'intégrité des membranes cellulaires. Indeed, polyunsaturated fatty acids (linoleic acid, linolenic acid, arachidonic acid) are essential for the integrity of cell membranes.
Ils interviennent dans le rôle de barriere conféré a l'épiderme qui controle la perte en eau de la peau. They intervene in the role of barrier conferred on the epidermis which controls the loss of water from the skin.
L'apport par voie topique de ces 3 acides gras essentiels et notamment de l'acide (-linolénique permet donc de conserver l'hydratation de la peau. The topical contribution of these 3 essential fatty acids and in particular of the acid (-linolenic thus makes it possible to preserve the hydration of the skin.
Des extraits tissulaires de rate, constituent le deuxième constituant essentiel renfermé par les compositions cosmétiques et dermatologiques selon l'invention. Ils renferment un mélange de peptides et de protéines obtenus par protéolyse de rate d'origine bovine. Tissue extracts from the spleen constitute the second essential constituent contained in the cosmetic and dermatological compositions according to the invention. They contain a mixture of peptides and proteins obtained by proteolysis of spleen of bovine origin.
La rate est un organe ayant un métabolisme très actif, riche en nutriments cellulaires de base et en particulier, en intermédiaires energétiques. I1 a été montré que les extraits de rate stimulent la croissance et la multiplication des cellules, notamment des fibroblastes et augmentent l'activation du métabolisme cellulaire en accroissant l'activité respiratoire cellulaire (augmentation de la consommation en oxygène des fibroblastes). The spleen is an organ with a very active metabolism, rich in basic cellular nutrients and in particular, in energetic intermediates. It has been shown that spleen extracts stimulate the growth and multiplication of cells, in particular fibroblasts and increase the activation of cell metabolism by increasing cellular respiratory activity (increased oxygen consumption by fibroblasts).
Ces dernières propriétés préviennent la diminution de l'activité métabolique cellulaire, principale cause de l'apparition de signes de vieillissement. These latter properties prevent the decrease in cellular metabolic activity, the main cause of the appearance of signs of aging.
Les extraits tissulaires de rate sont bénéfiques sur l'activité des cellules fibroblastiques du derme. L'huile d'onagre, comme il a déjà été dit plus-haut, a des effets bénéfiques dans la prévention du vieillissement épidermique et l'amélioration du tégument senescent. Tissue extracts from the spleen are beneficial for the activity of fibroblast cells in the dermis. Evening primrose oil, as already mentioned above, has beneficial effects in preventing epidermal aging and improving the seed coat.
I1 était donc intéressant d'associer les deux principes actifs afin d'obtenir des préparations cosmétiques ou dermatologiques d'action synergique sur les deux compartiments cutanés (épidermique et dermique) atteints au cours du vieillissement. It was therefore interesting to combine the two active ingredients in order to obtain cosmetic or dermatological preparations with synergistic action on the two skin compartments (epidermal and dermal) affected during aging.
A cet effet, l'association a été réalisée et la demanderesse a pu constater que l'application régulière des compositions selon l'invention permettait une amélioration très sensible de l'hydratation et de la souplesse de la peau ainsi qu'une atténuation des rides. To this end, the association has been made and the Applicant has been able to observe that the regular application of the compositions according to the invention allows a very noticeable improvement in the hydration and flexibility of the skin as well as a reduction in wrinkles. .
L'invention concerne notamment des compositions cosmétiques ou dermatologiques, caractérisées en ce qu'elles renferment 2 à 20 2 en poids d'huile d'onagre et 2 a 10 tt en poids d'extraits tissulaires de rate. The invention relates in particular to cosmetic or dermatological compositions, characterized in that they contain 2 to 20 2 by weight of evening primrose oil and 2 to 10 tt by weight of spleen tissue extracts.
Les compositions de l'invention peuvent également contenir de l'adénosine triphosphate (ATP) tel quel ou sous forme de riboside phosphorylé ou de sels et de l'adénosine 3'-5' monophosphate cyclique (AMP cyclique); les deux produits augmentent et/ou préservent le potentiel énergétique des cellules de la peau car 1'ATP est l'élément énergétique principal de la cellule et L'VAMP cyclique le messager intracellulaire responsable de toutes les phosphorylations indispensables a un certain nombre de réactions telles que l'utilisation énergétique des glucides (glycogénolyse) et des lipides (lipolyse des triglycérides). The compositions of the invention can also contain adenosine triphosphate (ATP) as such or in the form of phosphorylated riboside or salts and adenosine 3'-5 'cyclic monophosphate (cyclic AMP); both products increase and / or preserve the energy potential of skin cells because ATP is the main energy element of the cell and cyclic VAMP the intracellular messenger responsible for all the phosphorylations essential to a certain number of reactions such than the energy use of carbohydrates (glycogenolysis) and lipids (lipolysis of triglycerides).
L'invention concerne donc des compositions telles que définies cidessus caractérisées en ce qu'elles renferment en outre de l'adénosine triphosphate (ATP) et notamment caractérisées en ce qu'elles renferment 0,01 a 5 > en poids d'adénosine triphosphate. The invention therefore relates to compositions as defined above, characterized in that they also contain adenosine triphosphate (ATP) and in particular characterized in that they contain 0.01 to 5> by weight of adenosine triphosphate.
L'invention a aussi pour objet des compositions telles que définies ci-dessus caractérisées en ce qu'elles renferment en outre de l'adénosine 3'-5' monophosphate cyclique (AMP cyclique) et notamment caractérisées en ce qu'elles renferment 0,01 a 5 en poids d'adénosine 3'-5' monophosphate cyclique. A subject of the invention is also compositions as defined above, characterized in that they additionally contain adenosine 3'-5 'cyclic monophosphate (cyclic AMP) and in particular characterized in that they contain 0, 01 to 5 by weight of adenosine 3'-5 'cyclic monophosphate.
Les compositions peuvent aussi contenir de la caféine ou de la théophylline ou n'importe quel produit susceptible de les contenir par exemple : thé, cafe. En effet, la caféine et la théophylline sont des méthyl-xanthines inhibitrices de la phosphodiestenase, enzyme respondable de la dégradation de 1'AMP cyclique permettant ainsi de maintenir le taux d'AMP cyclique dans les compositions. The compositions can also contain caffeine or theophylline or any product capable of containing them, for example: tea, coffee. In fact, caffeine and theophylline are methyl-xanthines inhibitors of phosphodiestenase, an enzyme responsible for the degradation of cyclic AMP, thus making it possible to maintain the level of cyclic AMP in the compositions.
Eventuellement, les compositions selon l'invention peuvent contenir également de petites quantités de filtres ou écrans des radiations solaires. I7 s'agit par exemple de filtres des radiations UVA ET UVB tels que par exemple l'hydroxy 2-méthoxy 4-benzophène, l'acide diméthoxy 3,4-phényl glyoxylique sous forme de sel de sodium. Ces compositions selon l'invention peuvent aussi renfermer des produits bloqueurs de la formation des radicaux libres et d'oxygène singulets. Ces produits permettent d'arrêter les radiations solaires autres que les UV. Ces produits sont, par exemple, les terpènes, extrait liposoluble de
carotte, l' -tocophérol. Optionally, the compositions according to the invention may also contain small amounts of filters or screens for solar radiation. These are, for example, filters for UVA and UVB radiation such as, for example, hydroxy 2-methoxy 4-benzophene, dimethoxy 3,4-phenyl glyoxylic acid in the form of the sodium salt. These compositions according to the invention may also contain products blocking the formation of free radicals and singlet oxygen. These products stop solar radiation other than UV. These products are, for example, terpenes, fat-soluble extract of
carrot, -tocopherol.
Les compositions renferment aussi avantageusement des anti-oxydants tels que par exemple le < -oryzanol. Toutes les substances mentionnées
ci-dessus permettent de protéger la peau de toutes les radiations solaires nocives et d'obtenir une action photoprotectrice très efficace.The compositions also advantageously contain antioxidants such as for example <-oryzanol. All substances mentioned
above protect the skin from all harmful solar radiation and obtain a very effective photoprotective action.
Les compositions selon l'invention peuvent éventuellement renfermer des humectants favorisant l'hydratation de la peau, tels que l'urée, l'acide pyrrolidone carboxylique et ses sels, des extraits vitaminés, des parfums, des conservateurs, des colorants. The compositions according to the invention may optionally contain humectants promoting hydration of the skin, such as urea, pyrrolidone carboxylic acid and its salts, vitamin extracts, perfumes, preservatives, dyes.
Le collagène, l'élastine, l'acide hyaluronique, substances connues comme ayant des propriétés bienfaisantes sur la peau, peuvent aussi être présentes dans les compositions de l'invention. Collagen, elastin, hyaluronic acid, substances known to have beneficial properties on the skin, can also be present in the compositions of the invention.
On peut y ajouter un extrait de prêle ou toute autre substance contenant du silicium, qui améliore les effets du collagène et de l'acide hyaluronique. You can add horsetail extract or any other substance containing silicon, which improves the effects of collagen and hyaluronic acid.
Les compositions cosmetiques ou dermatologiques, selon l'invention peuvent se présenter sous toutes les formes utilisées en cosmétologie crème ou gel en pots ou en tubes, lait ou huile, lotion en flacon de verre ou de plastique et éventuellement en flacon-doseur, ou encore en ampoules. The cosmetic or dermatological compositions according to the invention can be in any form used in cosmetology cream or gel in jars or in tubes, milk or oil, lotion in a glass or plastic bottle and possibly in a dosing bottle, or else in ampoules.
L'invention concerne donc des compositions cosmétiques ou dermatologiques caractérisées en ce qu'elles se présentent sous forme de crème, gel, lait, lotion ou huile pour la peau et tout particulièrement, des compositions cosmétiques ou dermatologiques caractérisées en ce que leurs excipients sont adaptés a l'application sur le visage et sur le cou. The invention therefore relates to cosmetic or dermatological compositions characterized in that they are in the form of cream, gel, milk, lotion or oil for the skin and very particularly, cosmetic or dermatological compositions characterized in that their excipients are suitable when applied to the face and the neck.
En effet, pour chaque forme, on a recours a des excipients appropriés. Ces excipients doivent avoir toutes les qualités habituellement demandées. Ils doivent être doués d'une grande affinité pour la peau, être parfaitement bien tolérés, stables, présenter une consistance adéquate permettant une utilisation facile et agréable. A titre d'exemples d'excipients pouvant etre utilisés, on peut citer, pour la forme crème, le mélange myristate d'isopropyle, stéarate de glycérol, huile d'amandes douces, alcool cétylique, polyol (respectivement 5 g 15 g - 6 g - 1 g - 5 g pour 100 g d'eau distillée). Indeed, for each form, use is made of suitable excipients. These excipients must have all the qualities usually required. They must have a great affinity for the skin, be perfectly tolerated, stable, have an adequate consistency allowing easy and pleasant use. As examples of excipients which can be used, there may be mentioned, for the cream form, the mixture of isopropyl myristate, glycerol stearate, sweet almond oil, cetyl alcohol, polyol (respectively 5 g 15 g - 6 g - 1 g - 5 g per 100 g of distilled water).
Les émulgateurs sont par exemple un mélange de mêthyl glucoside sesquistéarate polyoxyéthyléné (20) et de méthyl glucoside sesquistéarate. The emulsifiers are, for example, a mixture of polyoxyethylenated methyl glucoside sesquistearate (20) and methyl glucoside sesquistearate.
Pour la forme lait, l'association monostéarate de sorbitan, éther cétylique polyoxyéthyle, huile de vaseline, palmitate d'isopropyle, cire d'abeille, polyol (respectivement 1 - 3 g - 5 g - 5 g - 1 g - 5 g pour 100 g d'eau distillée). Pour la forme gel, on utilise par exemple, un polymère carboxyvinylique associé à la triéthanolamine et à un ester d'acide gras (respectivement 3 g - 3 g - 5 g - pour 100 g d'eau distillée). Pour la forme huile, des triglycérides d'acides gras associés au perhydrosqualène (respectivement 30 g et 20 g pour 100 g d'huiles végétales). For the milk form, the combination of sorbitan monostearate, polyoxyethyl cetyl ether, petrolatum oil, isopropyl palmitate, beeswax, polyol (respectively 1 - 3 g - 5 g - 5 g - 1 g - 5 g for 100 g of distilled water). For the gel form, for example, a carboxyvinyl polymer is used combined with triethanolamine and a fatty acid ester (respectively 3 g - 3 g - 5 g - per 100 g of distilled water). For the oil form, triglycerides of fatty acids associated with perhydrosqualene (respectively 30 g and 20 g per 100 g of vegetable oils).
Les différentes formes cosmétiques mentionnées ci-dessus peuvent être obtenues selon les méthodes usuelles utilisées dans ce domaine. The various cosmetic forms mentioned above can be obtained according to the usual methods used in this field.
Les exemples suivants illustrent l'invention sans toutefois la limiter. The following examples illustrate the invention without, however, limiting it.
EXEMPLE 1 : Crème.EXAMPLE 1: Cream.
- esters d'acides gras.................................... 7 g - alcool cétylique........................................ 1 g - stéarate de glycérol et de PEG 100...................... 6 g - ester de propylène glycol et d'acides gras.............. 7 g - benzophénone ........................................... 1 g - huile d'onagre ................................... 5 g - propylène glycol.................................. 5 g - conservateurs .................................... q.s - polymère carboxyvinylique ............................... 0,5 g - triéthanol amine......................................... 0,5 g - extrait tissulaire de rate............................... 3 g - composition aromatique .................................. 9 g - eau distillée q. s. p.................................... 100 g
EXEMPLE 2 : Lait.- fatty acid esters .................................... 7 g - cetyl alcohol ... ..................................... 1 g - glycerol and PEG 100 stearate ... ................... 6 g - propylene glycol and fatty acid ester .............. 7 g - benzophenone. .......................................... 1 g - evening primrose oil. .................................. 5 g - propylene glycol ........... ....................... 5 g - preservatives ....................... ............. qs - carboxyvinyl polymer ............................... 0, 5 g - triethanol amine ......................................... 0.5 g - spleen tissue extract ............................... 3 g - aromatic composition ......... ......................... 9 g - distilled water qs ................... ................ 100 g
EXAMPLE 2: Milk.
- stéarate de glycérol et de PEG 100........................ 5 g - huile de vaseline......................................... 3 g - huile de silicone......................................... 1 g - dérivé de lanoline........................................ 8 g - huile d'onagre............................................ 3 g - sorbitol ................................................. 5 g - extrait tissulaire de rate................................ 2 g - polymère carboxyvinylique 0,5 g - triéthanol ami ne 0,5 g - conservateurs q.s - composition aromatique q.s - eau distillée q. s. p..................................... 100 g
Exemple 3 : Crème.- glycerol and PEG 100 stearate ........................ 5 g - vaseline oil ............ ............................. 3 g - silicone oil ............... .......................... 1 g - lanolin derivative .................. ...................... 8 g - evening primrose oil ..................... ....................... 3 g - sorbitol ....................... .......................... 5 g - tissue extract of spleen ................. ............... 2 g - carboxyvinyl polymer 0.5 g - triethanol friendly 0.5 g - preservatives qs - aromatic composition qs - distilled water qs ....... ............................. 100 g
Example 3: Cream.
- Lipides d'origine naturelle et synthétiques .............. 15 g - Huile d'onagre ........................................... 8 g - Mélange de mono, di. et trialkylglycoléther-o-phosphates . 5 g - Filtres solaires UV.A et UV.B ............................ 2 g - #-Orizanol ............................................... 0,5 g - Polymère carboxy vinylique ............................... 0,7 g - Triéthanolamine .......................................... 0,6 g - Extrait tissulaire de rate ............................... 3 g - Extrait de café/thé ...................................... 5 g - Extrait de prêle ........................................ 1 g - ATP sel disodique ........................................ 0,02g - Urée ..................................................... 0,5 g - Conservateurs ............................................ q.s.- Natural and synthetic lipids .............. 15 g - Evening primrose oil ..................... ...................... 8 g - Mixture of mono, di. and trialkylglycolether-o-phosphates. 5 g - UV.A and UV.B sun filters ............................ 2 g - # -Orizanol .... ........................................... 0.5 g - Carboxy polymer vinyl ............................... 0.7 g - Triethanolamine ............ .............................. 0.6 g - Tissue extract from spleen ........... .................... 3 g - Coffee / tea extract ...................... ................ 5 g - Horsetail extract ............................ ............ 1 g - ATP disodium salt ................................ ........ 0.02g - Urea ..................................... ................ 0.5 g - Preservatives ............................ ................ qs
- Composition aromatique contenant des terpenes ............ q.s.- Aromatic composition containing terpenes ............ q.s.
- Eau ................................................q.s.p. 100 g
Exemple 4 : Crème.- Water ................................................ qs 100 g
Example 4: Cream.
- Glucate SS soit méthyl glucoside sesquistéarate .......... 3 g - Glucamate SSE 20 soit méthyl glucoside polyoxyéthylene 20
sesquistéarate ........................................ 2 g - Huile d'onagre ........................................... 10 g - Esters d'acides gras ..................................... 7 g - Stérols d'origine végétale ............................... 5 g - Extrait liposoluble de carotte ........................... 0,2 g - #-Tocophérol (vitamine E) ................................ 0,05g - Filtres solaires UV.A et UV.B ............................ 3 g - Magnésium aluminium silicate ............................. 1,2 g - Extrait tissulaire de rate ............................... 5 g - Conservateurs ............................................ q.s.- Glucate SS or methyl glucoside sesquistearate .......... 3 g - Glucamate SSE 20 or methyl glucoside polyoxyethylene 20
sesquistearate ........................................ 2 g - Evening primrose oil .. ......................................... 10 g - Esters of fatty acids. .................................... 7 g - Sterols of plant origin ...... ......................... 5 g - Fat-soluble carrot extract .................. ......... 0.2 g - # -Tocopherol (vitamin E) ............................. ... 0.05g - UV.A and UV.B sun filters ............................ 3 g - Magnesium aluminum silicate ............................. 1.2 g - Tissue extract from spleen ............ ................... 5 g - Preservatives ........................... ................. qs
- Pyrrolidone carboxylate de sodium ........................ 2 g - Acide hyaluronique ....................................... 0,03g - Riboside phosphoryle d' ATP .............................. 0,025g - AMP cyclique ............................................. 0,02g - Composition aromatique ................................... 0,3 g - Eau .................................................q.s.p 100 g - Sodium pyrrolidone carboxylate ........................ 2 g - Hyaluronic acid ................ ....................... 0.03g - ATP phosphorylated riboside .................. ............ 0.025g - cyclic AMP ................................. ............ 0.02g - Aromatic composition ................................ ... 0.3 g - Water ......................................... ........ qs 100 g
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8616154A FR2606279B1 (en) | 1984-12-19 | 1986-11-20 | NOVEL COMPOSITIONS CONTAINING PRIMER OIL AND BLOCKING PRODUCTS FROM THE FORMATION OF FREE RADICALS AND SINGULATED OXYGEN |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8419446A FR2574661B3 (en) | 1984-12-19 | 1984-12-19 | NOVEL SKIN CARE COMPOSITIONS CONTAINING PRIMER OIL AND RATE TISSUE EXTRACTS |
| FR8616154A FR2606279B1 (en) | 1984-12-19 | 1986-11-20 | NOVEL COMPOSITIONS CONTAINING PRIMER OIL AND BLOCKING PRODUCTS FROM THE FORMATION OF FREE RADICALS AND SINGULATED OXYGEN |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2606279A1 true FR2606279A1 (en) | 1988-05-13 |
| FR2606279B1 FR2606279B1 (en) | 1994-02-18 |
Family
ID=26224290
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8616154A Expired - Fee Related FR2606279B1 (en) | 1984-12-19 | 1986-11-20 | NOVEL COMPOSITIONS CONTAINING PRIMER OIL AND BLOCKING PRODUCTS FROM THE FORMATION OF FREE RADICALS AND SINGULATED OXYGEN |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR2606279B1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000018416A1 (en) * | 1998-09-30 | 2000-04-06 | Industrial Research Limited | Antioxidant compositions and process for their preparation |
| EP1520577A1 (en) * | 2003-09-30 | 2005-04-06 | Kneipp-Werke Kneipp-Mittel-Zentrale GmbH & CO. KG | Cosmetic or dermatological composition comprising oil of evening primrose |
| FR2903014A1 (en) * | 2006-06-30 | 2008-01-04 | Occitane L | COSMETIC COMPOSITION BASED ON POLYUNSATURATED FATTY ACIDS AND USES THEREOF |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2557452A1 (en) * | 1983-12-28 | 1985-07-05 | Roussel Uclaf | NOVEL COMPOSITIONS FOR SKIN CARE CONTAINING PRIMER OIL AND RATE TISSUE TRAITS |
-
1986
- 1986-11-20 FR FR8616154A patent/FR2606279B1/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2557452A1 (en) * | 1983-12-28 | 1985-07-05 | Roussel Uclaf | NOVEL COMPOSITIONS FOR SKIN CARE CONTAINING PRIMER OIL AND RATE TISSUE TRAITS |
Non-Patent Citations (1)
| Title |
|---|
| DICTIONNAIRE VIDAL, 1984, 4ème partie, pages 87-88, O.V.P., Paris, FR; "Onagrine" * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000018416A1 (en) * | 1998-09-30 | 2000-04-06 | Industrial Research Limited | Antioxidant compositions and process for their preparation |
| EP1520577A1 (en) * | 2003-09-30 | 2005-04-06 | Kneipp-Werke Kneipp-Mittel-Zentrale GmbH & CO. KG | Cosmetic or dermatological composition comprising oil of evening primrose |
| FR2903014A1 (en) * | 2006-06-30 | 2008-01-04 | Occitane L | COSMETIC COMPOSITION BASED ON POLYUNSATURATED FATTY ACIDS AND USES THEREOF |
| WO2008000974A3 (en) * | 2006-06-30 | 2008-03-06 | Occitane L | Cosmetic composition based on polyunsaturated fatty acids and its uses |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2606279B1 (en) | 1994-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CH661205A5 (en) | COSMETIC OR DERMATOLOGICAL COMPOSITIONS FOR SKIN CARE. | |
| US20050266064A1 (en) | Cosmetic compositions and methods | |
| KR101972071B1 (en) | Cosmetic composition for improving skin tone or skin elasticity | |
| FR2671487A1 (en) | USE OF A GROWTH FACTOR IN A SLIMMING COMPOSITION. | |
| EP1064931A1 (en) | Cosmetic composition containing at least an hydroxystilbene and ascorbic acid | |
| EP1278532B1 (en) | Plant extract of the olea europaea species as no-synthase inhibitor and uses | |
| EP0909556B1 (en) | Rosaceae extract as bradykinin antagonist | |
| EP0399909A1 (en) | Cosmetic composition against skin ageing | |
| EP0938891A1 (en) | Cosmetic composition containing cinnamic acid or its derivatives and its use | |
| CH669727A5 (en) | ||
| EP0655235A1 (en) | Slimming composition | |
| CA2407311A1 (en) | Plant extract of the species vitis vinifera as no-synthase inhibitor and uses | |
| WO1990006104A1 (en) | Use of kaempferol and certain derivatives thereof for the preparation of a cosmetic or pharmaceutical composition | |
| FR2574661A1 (en) | New skin care compositions containing Oenothera oil and spleen tissue extracts | |
| FR2606279A1 (en) | New compositions containing Oenothera oil and products that block the formation of singlet oxygen and free radicals | |
| EP1232744B1 (en) | Composition containing vitamin C prepared during application | |
| EP1768684B1 (en) | Composition comprising a blue lotus extract for the treatment of facial uncontrolled muscular contractions | |
| FR2609630A1 (en) | New cosmetic or dermatological compositions containing an extract of Silybum marianum fruits which is rich in silymarin combined with essential fatty acids | |
| EP1811953B1 (en) | Novel use of chaulmoogra oil and guggulipids in therapeutics and cosmetics | |
| FR2801789A1 (en) | Compositions comprise keratolin, a lipogenesis inhibitor and excipients for topical application, have a slimming effects on the face | |
| KR101957380B1 (en) | Cosmetic composition comprising fermented product of animal oil for improving skin ealsticity moisture | |
| CA2278226C (en) | Cosmetic or dermo-phamaceutical products compatible with cutaneous ecology | |
| FR2633829A1 (en) | Cosmetic composition and cosmetic hair-care product containing this composition | |
| EP1316301A1 (en) | Cosmetic or dermatological composition containing a retinoid and/or a carotenoid and acexamic acid | |
| FR2821549A1 (en) | USE OF A CAROTENOID TO TREAT THE SIGNS OF AGING |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |